GLP-1 receptor agonists work because they mimic a hormone your gut already produces — but more strongly and for much longer than the natural version. The result is a coordinated set of effects on blood sugar, appetite, gastric emptying, and brain reward systems.
When you eat, specialized cells in your intestine release GLP-1 within minutes. The natural hormone is broken down by an enzyme (DPP-4) within 1–2 minutes. In that brief window, it tells the pancreas to release insulin (glucose-dependent), suppresses glucagon, slows gastric emptying, and signals satiety to the brain.
The drugs in this class are engineered to resist DPP-4 breakdown. Semaglutide has a half-life of ~7 days, allowing once-weekly dosing. The signal that GLP-1 would normally send for minutes is now sustained continuously.
Beyond glucose and appetite, direct effects on the cardiovascular system (reduced inflammation, possible vascular endothelium and myocardium effects), kidney (reduced glomerular hyperfiltration), and liver (improved insulin sensitivity, reduced lipogenesis). These effects are not solely consequences of weight loss — the magnitude is too large.
For the trial evidence behind these mechanisms, see our research bibliography.